Ziftomenib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 200 mg
Reference Brands: Komzifti (USA)
Category:
Oncology Cancer Care
Ziftomenib is a small‑molecule menin inhibitor. It blocks the interaction between menin and MLL proteins, disrupting a pathway critical for the survival and proliferation of certain leukemia cells, especially those with NPM1 mutation or MLL rearrangement. It is used in adult patients with relapsed or refractory AML who have no satisfactory alternative treatment options.
Ziftomenib is available in Capsules
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ziftomenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ziftomenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing